Top Markets
#1 Black Phoenix Black Phoenix +355.53%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +65.70%
#4 Gold Park Gold Park +62.71%
#5 OpenEden OpenEden +56.54%
#6 BasedHype BasedHype +27.42%
#7 Avantis Avantis +22.22%
#8 Cryptopia Cryptopia +21.54%
#9 Acurast Acurast +18.38%
#10 Humanity Humanity +17.96%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Classifica tra le azioni #40469
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Prezzo delle azioni
$0.00204105
Capitalizzazione di mercato
$138.92K
Variazione (1 giorno)
5.63%
Variazione (1 anno)
-60.44%
Paese
GB
Scambia Solvonis Therapeutics plc (SVNS)

Categoria

Industrials
Ricavi di Solvonis Therapeutics plc (SVNS)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Solvonis Therapeutics plc, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Solvonis Therapeutics plc da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Lam Research Corp. R Lam Research Corp. R
Lam Research Corp. R
LAR0.DE
 - -
US
Siemens AG Siemens AG
Siemens AG
SIE.DE
 $94.53B -
DE
Schneider Electric S.E. Schneider Electric S.E.
Schneider Electric S.E.
SU.PA
 - -
FR
Siemens Energy AG Siemens Energy AG
Siemens Energy AG
ENR.DE
 - -
DE
Parker-Hannifin Corporation Parker-Hannifin Corporation
Parker-Hannifin Corporation
PH.US
 $21.50B -
US